Form 4: GALT CFO Sells Shares After RSU Vesting

Sentiment:

Insider Transaction Report 6 January 2026 4:54 PM

📋All filings for Galectin Therapeutics INC

Galectin Therapeutics CFO Jack W. Callicutt reported the sale of common stock following the vesting of restricted stock units under a pre-arranged 10b5-1 plan.

Worse than expectedThe Chief Financial Officer sold a substantial portion of their holdings (60,000 shares) over a short period.The sales occurred at progressively lower prices, from $4.1968 to $3.6698, which could be interpreted negatively by the market.While conducted under a 10b5-1 plan, significant insider selling, especially by a CFO, can be perceived as a lack of confidence or a move to diversify personal wealth away from the company's stock.

Summary

Chief Financial Officer Jack W. Callicutt reported multiple transactions involving Galectin Therapeutics Inc. common stock.
On January 2, 2026, 60,000 shares of common stock were acquired for no additional consideration due to the vesting of Restricted Stock Units.
Also on January 2, 2026, 13,914 shares were sold at a weighted average price of $4.1968 per share.
On January 5, 2026, an additional 25,732 shares were sold at a weighted average price of $3.8978 per share.
On January 6, 2026, a further 20,354 shares were sold at a weighted average price of $3.6698 per share.
All sales were conducted pursuant to a Rule 10b5-1 plan adopted on April 17, 2025.
Following these transactions, the reporting person beneficially owns 7,614 shares of common stock.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by the CFO, even though it was pre-planned. While the RSU vesting is a positive for the individual, the subsequent sales at declining prices can be perceived as a lack of strong conviction in the near-term stock performance by a key executive.

Positives

The acquisition of 60,000 shares of common stock resulted from the vesting of Restricted Stock Units, indicating a prior compensation award.

Negatives

Chief Financial Officer Jack W. Callicutt sold a total of 60,000 shares of common stock across three transactions between January 2, 2026, and January 6, 2026.
The sales occurred at decreasing weighted average prices: $4.1968, $3.8978, and $3.6698.
The total number of shares beneficially owned by the CFO decreased significantly from 67,614 to 7,614 after the reported transactions.

Future Outlook

Industry Context

This is a routine insider transaction filing for a publicly traded company. It reflects a key executive's personal stock activity rather than broader industry trends or competitive positioning.

Stakeholder Impact

Shareholders: May view the significant insider selling by the CFO as a negative signal, potentially leading to downward pressure on the stock price.
Employees: No direct impact mentioned, but could affect morale if perceived negatively.

Key Dates

Date	Description
2025-04-17	Date Rule 10b5-1 plan was adopted by the reporting person.
2025-08-14	Date Issuer's Quarterly Report on Form 10-Q, disclosing the 10b5-1 plan, was filed with the SEC.
2026-01-01	Date Restricted Stock Units became exercisable.
2026-01-02	Date of earliest transaction, including RSU vesting and initial stock sale.
2026-01-05	Date of second stock sale transaction.
2026-01-06	Date of third stock sale transaction and filing date of the Form 4.

Recommendation

sell

The significant sale of shares by the Chief Financial Officer, even under a 10b5-1 plan, and particularly at declining prices, suggests a lack of strong conviction in the company's immediate future stock performance. While the vesting of RSUs is a normal compensation event, the subsequent liquidation of the entire vested amount and more (reducing beneficial ownership from 67,614 to 7,614 shares) by a key executive is a strong negative signal for investors. This action could indicate that the insider believes the stock is fully valued or that better opportunities exist elsewhere, prompting a recommendation to sell or reduce exposure.

Keywords

Galectin Therapeutics, GALT, Form 4, Insider Trading, Stock Sale, CFO, Jack W. Callicutt, Restricted Stock Units, RSU Vesting, 10b5-1 Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.